Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 3.20
NAS:SNSS's Cash-to-Debt is ranked lower than
69% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:SNSS: 3.20 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SNSS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.69  Med: 9.06 Max: No Debt
Current: 3.2
Equity-to-Asset 0.40
NAS:SNSS's Equity-to-Asset is ranked lower than
78% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:SNSS: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SNSS' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.31  Med: 0.48 Max: 0.89
Current: 0.4
-3.31
0.89
Debt-to-Equity 0.57
NAS:SNSS's Debt-to-Equity is ranked lower than
86% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:SNSS: 0.57 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SNSS' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.8  Med: 0.31 Max: 21.6
Current: 0.57
-3.8
21.6
Piotroski F-Score: 2
Altman Z-Score: -36.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1350.88
NAS:SNSS's Operating Margin % is ranked lower than
81% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:SNSS: -1350.88 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SNSS' s Operating Margin % Range Over the Past 10 Years
Min: -64863.64  Med: -745.14 Max: -399.36
Current: -1350.88
-64863.64
-399.36
Net Margin % -1410.02
NAS:SNSS's Net Margin % is ranked lower than
82% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:SNSS: -1410.02 )
Ranked among companies with meaningful Net Margin % only.
NAS:SNSS' s Net Margin % Range Over the Past 10 Years
Min: -74506.06  Med: -909.61 Max: -401.09
Current: -1410.02
-74506.06
-401.09
ROE % -300.97
NAS:SNSS's ROE % is ranked lower than
93% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:SNSS: -300.97 )
Ranked among companies with meaningful ROE % only.
NAS:SNSS' s ROE % Range Over the Past 10 Years
Min: -1585.52  Med: -167.56 Max: -57.33
Current: -300.97
-1585.52
-57.33
ROA % -110.87
NAS:SNSS's ROA % is ranked lower than
87% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:SNSS: -110.87 )
Ranked among companies with meaningful ROA % only.
NAS:SNSS' s ROA % Range Over the Past 10 Years
Min: -448.13  Med: -81.16 Max: -39.99
Current: -110.87
-448.13
-39.99
ROC (Joel Greenblatt) % -399906.98
NAS:SNSS's ROC (Joel Greenblatt) % is ranked lower than
99% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:SNSS: -399906.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SNSS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -427082.35  Med: -46443.7 Max: -859.84
Current: -399906.98
-427082.35
-859.84
3-Year Revenue Growth Rate -43.80
NAS:SNSS's 3-Year Revenue Growth Rate is ranked lower than
84% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:SNSS: -43.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SNSS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -90.9  Med: -43.8 Max: 385.2
Current: -43.8
-90.9
385.2
3-Year EBITDA Growth Rate -14.00
NAS:SNSS's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:SNSS: -14.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SNSS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.6  Med: -35.2 Max: 16.2
Current: -14
-59.6
16.2
3-Year EPS without NRI Growth Rate -15.10
NAS:SNSS's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:SNSS: -15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SNSS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.4  Med: -17.9 Max: 21
Current: -15.1
-60.4
21
GuruFocus has detected 3 Warning Signs with Sunesis Pharmaceuticals Inc $NAS:SNSS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SNSS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SNSS Guru Trades in Q3 2016

Jim Simons 94,581 sh (+108.38%)
First Eagle Investment 249,999 sh (unchged)
» More
Q4 2016

SNSS Guru Trades in Q4 2016

First Eagle Investment 574,999 sh (+130.00%)
Jim Simons 110,581 sh (+16.92%)
» More
Q1 2017

SNSS Guru Trades in Q1 2017

Jim Simons 111,811 sh (+1.11%)
First Eagle Investment 319,480 sh (-44.44%)
» More
Q2 2017

SNSS Guru Trades in Q2 2017

First Eagle Investment 319,480 sh (unchged)
Jim Simons 90,681 sh (-18.90%)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-03-31 Reduce -44.44%$3.76 - $4.3 $ 1.96-52%319,480
First Eagle Investment 2016-12-31 Add 130.00%0.01%$3.49 - $4.71 $ 1.96-51%574,999
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GNMX, NAS:OVAS, NAS:MBRX, AMEX:ATNM, NAS:KMPH, NAS:OPNT, NAS:AZRX, OTCPK:PNTV, NAS:PTI, NAS:LPTX, NAS:HSGX, OTCPK:ORGS, OTCPK:NWBO, NAS:APVO, OTCPK:ANTB, NAS:ADMA, NAS:NTRP, NAS:NVIV, OTCPK:CDXI, NAS:CHMA » details
Traded in other countries:RYIP.Germany,
Headquarter Location:USA
Sunesis Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.

Sunesis Pharmaceuticals Inc was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is an anti-cancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. In October 2014, the Company announced the results of a Phase 3, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, commonly used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine, and was conducted at 124 study sites in the U.S., Canada, Europe, South Korea, Australia and New Zealand. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.

Top Ranked Articles about Sunesis Pharmaceuticals Inc

Sunesis to Present at Upcoming Investor Conferences
Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies
Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting
Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc., ImmunoCellular Therapeutics, Ltd., KBR, Inc., Sunesis Pharmaceuticals, Inc., Sunrun Inc. and Vince Holding Corp.
Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuticals, Inc. (SNSS)

Ratios

vs
industry
vs
history
PS Ratio 17.98
SNSS's PS Ratio is ranked lower than
59% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. SNSS: 17.98 )
Ranked among companies with meaningful PS Ratio only.
SNSS' s PS Ratio Range Over the Past 10 Years
Min: 1.71  Med: 21.21 Max: 936
Current: 17.98
1.71
936
EV-to-EBIT -1.43
SNSS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. SNSS: -1.43 )
Ranked among companies with meaningful EV-to-EBIT only.
SNSS' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.8  Med: -2.2 Max: 1.2
Current: -1.43
-10.8
1.2
EV-to-EBITDA -1.43
SNSS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. SNSS: -1.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNSS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.8  Med: -2.3 Max: 1.2
Current: -1.43
-10.8
1.2
EV-to-Revenue 19.22
SNSS's EV-to-Revenue is ranked lower than
62% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. SNSS: 19.22 )
Ranked among companies with meaningful EV-to-Revenue only.
SNSS' s EV-to-Revenue Range Over the Past 10 Years
Min: -422.2  Med: 20.1 Max: 2671.7
Current: 19.22
-422.2
2671.7
Current Ratio 3.37
SNSS's Current Ratio is ranked lower than
58% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. SNSS: 3.37 )
Ranked among companies with meaningful Current Ratio only.
SNSS' s Current Ratio Range Over the Past 10 Years
Min: 0.71  Med: 3.08 Max: 12.17
Current: 3.37
0.71
12.17
Quick Ratio 3.37
SNSS's Quick Ratio is ranked lower than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. SNSS: 3.37 )
Ranked among companies with meaningful Quick Ratio only.
SNSS' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 3.08 Max: 12.17
Current: 3.37
0.71
12.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.20
SNSS's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. SNSS: -32.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNSS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -197.7  Med: -32.2 Max: -6.2
Current: -32.2
-197.7
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.46
SNSS's Price-to-Net-Cash is ranked higher than
72% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. SNSS: 4.46 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SNSS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.7  Med: 3.47 Max: 194.73
Current: 4.46
1.7
194.73
Price-to-Median-PS-Value 0.85
SNSS's Price-to-Median-PS-Value is ranked higher than
60% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SNSS: 0.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNSS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.91 Max: 44.57
Current: 0.85
0.05
44.57
Earnings Yield (Greenblatt) % -69.93
SNSS's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. SNSS: -69.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNSS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -77335.9  Med: -43.15 Max: 16999.7
Current: -69.93
-77335.9
16999.7

More Statistics

Revenue (TTM) (Mil) $2.57
EPS (TTM) $ -1.88
Beta0.35
Short Percentage of Float1.86%
52-Week Range $1.86 - 5.00
Shares Outstanding (Mil)23.51

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.76 -1.77
EPS without NRI ($) -1.76 -1.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
Sunesis to Present at Upcoming Investor Conferences Aug 31 2017 
Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Re Jul 24 2017 
Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covale Jul 18 2017 
Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsor Jun 23 2017 
Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc., Immu May 15 2017 
Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights May 08 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for May 02 2017 
SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50, May 02 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmace May 02 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuti May 02 2017 

More From Other Websites
Sunesis to Present at Upcoming Investor Conferences Aug 31 2017
Edited Transcript of SNSS earnings conference call or presentation 27-Jul-17 6:00pm GMT Aug 13 2017
Sunesis reports 2Q loss Jul 27 2017
Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights Jul 27 2017
Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and... Jul 24 2017
Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral... Jul 18 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc.... May 19 2017
The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug May 19 2017
Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc.,... May 15 2017
Edited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT May 12 2017
ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017 May 11 2017
Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
Investor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call May 08 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis... May 04 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis... May 03 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals,... May 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}